Results 71 to 80 of about 3,285 (205)

Molecular monitoring of plasmodium falciparum drug susceptibility at the time of the introduction of artemisinin-based combination therapy in Yaoundé, Cameroon: Implications for the future

Malaria Journal, 2012
Background Regular monitoring of the levels of anti-malarial resistance of Plasmodium falciparum is an essential policy to adapt therapy and improve malaria control.
Menard Sandie, Morlais Isabelle, Tahar Rachida, Sayang Collins, Mayengue Pembe, Iriart Xavier, Benoit-Vical Françoise, Lemen Brigitte, Magnaval Jean-François, Awono-Ambene Parfait, Basco Leonardo K, Berry Antoine   +11 more
doaj   +1 more source

Stable high frequencies of sulfadoxine–pyrimethamine resistance associated mutations and absence of K13 mutations in Plasmodium falciparum 3 and 4 years after the introduction of artesunate plus sulfadoxine–pyrimethamine in Ujjain, Madhya Pradesh, India

Malaria Journal, 2020
Background Artesunate plus sulfadoxine–pyrimethamine (ASP) is first-line treatment for uncomplicated Plasmodium falciparum malaria in most of India, except for six North-eastern provinces where treatment failure rates were high. In Ujjain, central India,
Ashish Pathak, Andreas Mårtensson, Sudhir Gawariker, Ashish Sharma, Vishal Diwan, Manju Purohit, Johan Ursing   +6 more
doaj   +1 more source

Malaria in Bangladesh, 2000–2025: Navigating the Headwinds From Control to Elimination

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims Bangladesh has dramatically reduced its malaria burden since 2000, confining the disease to specific geographic zones. However, the national 2030 elimination goal is now threatened by a complex interplay of biological, ecological, and social factors.
Abdullaha Al Mamun, Mustafa Sarwar A. Kayenat, K. A. M. Inzamul Islam   +2 more
wiley   +1 more source

Roles of PfMDR1 and PfCRT in the parasite’s susceptibility to lumefantrine, mefloquine, and chloroquine.

, 2022
Mechanistic explanations for how polymorphisms in pfmdr1 and pfcrt alter the parasite’s response to lumefantrine and mefloquine (a) and chloroquine (b).
Ben Corry (135521), Sarah Heckmatt Shafik (12501305), Sashika Natasha Richards (12501308), Rowena Elizabeth Martin (12501311)   +3 more
core   +1 more source

Polymorphism analysis of pfmdr1 gene in Plasmodium falciparum isolates 11 years post-adoption of artemisinin-based combination therapy in Saudi Arabia

Scientific Reports, 2022
A total of 227 Plasmodium falciparum isolates from Jazan region, southwestern Saudi Arabia were amplified for the P. falciparum multi-drug resistance 1 (pfmdr1) gene to detect point mutations 11 years after the introduction of artemisinin-based ...
Hesham M. Al-Mekhlafi, Aymen M. Madkhali, Ahmed A. Abdulhaq, Wahib M. Atroosh, Ahmad Hassn Ghzwani, Khalid Ammash Zain, Khalid Y. Ghailan, Hassan A. Hamali, Abdullah A. Mobarki, Talal H. Alharazi, Zaki M. Eisa, Yee-Ling Lau   +11 more
doaj   +1 more source

Unveiling Antimalarial Drug Resistance: The Role of CRISPR‐Cas Technologies in Malaria Research

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Background Malaria, caused by Plasmodium parasites, remains a global health burden, with drug resistance threatening control efforts. CRISPR‐Cas technologies, particularly CRISPR‐Cas9, have transformed malaria research by enabling precise genetic manipulations to study antimalarial resistance mechanisms, develop novel therapeutics and enhance ...
Reuben Samson Dangana, Israel Ehizuelen Ebhohimen, Moses Okpeku, Jess Vergis   +3 more
wiley   +1 more source

Mefloquine Exposure Induces Cell Cycle Delay and Reveals Stage-Specific Expression of the pfmdr1 Gene [PDF]

, 2013
Drug-resistant Plasmodium falciparum malaria is a major public health problem. An elevated pfmdr1 gene copy number (CN) is known to decrease parasite sensitivity to the commonly used antimalarial mefloquine (MFQ).
Kim, H.-S., Juliano, J. J., Bohorquez, E. B., Meshnick, S. R.   +3 more
core   +1 more source

Prevalence and factors associated with carriage of Pfmdr1 polymorphisms among pregnant women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and artemether-lumefantrine for malaria treatment in Burkina Faso

Malaria Journal, 2020
Background Single nucleotide polymorphisms occurring in the Plasmodium falciparum multidrug resistant gene 1 (pfmdr1) are known to be associated with aminoquinoline resistance and, therefore, represent key P.
Hamtandi Magloire Natama, Rouamba Toussaint, Djamina Line Cerine Bazié, Sékou Samadoulougou, Maminata Coulibaly-Traoré, Halidou Tinto, Fati Kirakoya-Samadoulougou   +6 more
doaj   +1 more source

PFMDR1 AND IN VIVO RESISTANCE TO ARTESUNATE-MEFLOQUINE IN FALCIPARUM MALARIA ON THE CAMBODIAN–THAI BORDER [PDF]

, 2007
Artemisinin combination therapies (ACTs) have recently been adopted as first-line therapy for Plasmodium falciparum infections in most malaria-endemic countries.
FANDEUR, Thierry, ALKER, Alisa, SEM, Rithy, LIM, Pharath, MEY BOUTH, Denis, ARIEY, Frederic, MAGUIRE, Jason, WONGSRICHANALAI, Chansuda, YI, Poravuth, TSUYUOKA, Reiko, MESHNICK, Steven, SHAH, Naman   +11 more
core   +1 more source

Image1_Plasmodium falciparum Drug Resistance Genes pfmdr1 and pfcrt In Vivo Co-Expression During Artemether-Lumefantrine Therapy.jpeg

, 2022
Background: Artemisinin-based combination therapies (ACTs) are the global mainstay treatment of uncomplicated Plasmodium falciparum infections. PfMDR1 and PfCRT are two transmembrane transporters, associated with sensitivity to several antimalarials ...
A. Björkman (6249143), A. Mårtensson (6249191), S. D. Otienoburu (12611293), M. Silva (7447316), J. P. Gil (12611299), M. Malmberg (12611290), B. Ngasala (12611296), M. I. Veiga (12611302)   +7 more
core   +1 more source